Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2020 Dec 28

PMID 33364237

Citations 17

Authors

Jing-Quan Wang

Qiu-Xu Teng

Zi-Ning Lei

Ning Ji

Qingbin Cui

Han Fu

Lizhu Lin

Dong-Hua Yang

Ying-Fang Fan

Zhe-Sheng Chen

Affiliations

Soon will be listed here.

Abstract

Overexpression of ABCG2 remains a major impediment to successful cancer treatment, because ABCG2 functions as an efflux pump of chemotherapeutic agents and causes clinical multidrug resistance (MDR). Therefore, it is important to uncover effective modulators to circumvent ABCG2-mediated MDR in cancers. In this study, we reported that AZ-628, a RAF kinase inhibitor, effectively antagonizes ABCG2-mediated MDR . Our results showed that AZ-628 completely reversed ABCG2-mediated MDR at a non-toxic concentration (3 μM) without affecting ABCB1-, ABCC1-, or ABCC10 mediated MDR. Further studies revealed that the reversal mechanism was by attenuating ABCG2-mediated efflux and increasing intracellular accumulation of ABCG2 substrate drugs. Moreover, AZ-628 stimulated ABCG2-associated ATPase activity in a concentration-dependent manner. Docking and molecular dynamics simulation analysis showed that AZ-628 binds to the same site as ABCG2 substrate drugs with higher score. Taken together, our studies indicate that AZ-628 could be used in combination chemotherapy against ABCG2-mediated MDR in cancers.

Citing Articles

Gold complex QB1561 suppresses drug-resistant cancer cells by inhibiting TrxR and mitochondrial respiratory function.

Gao H, Ding W, Shen Z, Cui Q Front Pharmacol. 2025; 16:1560880.

PMID: 40066335 PMC: 11891169. DOI: 10.3389/fphar.2025.1560880.

BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells.

Zanre V, Bellinato F, Cardile A, Passarini C, Di Bella S, Menegazzi M Int J Mol Sci. 2024; 25(22).

PMID: 39596009 PMC: 11593403. DOI: 10.3390/ijms252211939.

RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells.

Dong X, Lu Q, Li Y, Cai C, Teng Q, Lei Z J Transl Int Med. 2024; 12(3):288-298.

PMID: 39081282 PMC: 11284896. DOI: 10.2478/jtim-2024-0011.

Dorsomorphin attenuates ABCG2-mediated multidrug resistance in colorectal cancer.

Li X, Cao L, Yu Z, He K, Ding P, Li J Front Pharmacol. 2024; 15:1393693.

PMID: 38855753 PMC: 11157230. DOI: 10.3389/fphar.2024.1393693.

Nortriptyline hydrochloride, a potential candidate for drug repurposing, inhibits gastric cancer by inducing oxidative stress by triggering the Keap1-Nrf2 pathway.

Zhu C, Lu Y, Wang S, Song J, Ding Y, Wang Y Sci Rep. 2024; 14(1):6050.

PMID: 38480798 PMC: 10937941. DOI: 10.1038/s41598-024-56431-5.

References

Taylor N, Manolaridis I, Jackson S, Kowal J, Stahlberg H, Locher K . Structure of the human multidrug transporter ABCG2. Nature. 2017; 546(7659):504-509. DOI: 10.1038/nature22345. View

Gottesman M, Ambudkar S . Overview: ABC transporters and human disease. J Bioenerg Biomembr. 2002; 33(6):453-8. DOI: 10.1023/a:1012866803188. View

Ji N, Yang Y, Cai C, Wang J, Lei Z, Wu Z . Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an Study. Front Oncol. 2019; 9:514. PMC: 6591272. DOI: 10.3389/fonc.2019.00514. View

Robey R, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz A . Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res. 2001; 7(1):145-52. View

Zhang L, Li Y, Wang Q, Chen Z, Li X, Wu Z . The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol Cancer. 2020; 19(1):10. PMC: 6966863. DOI: 10.1186/s12943-019-1112-1. View

Borst P, Elferink R . Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002; 71:537-92. DOI: 10.1146/annurev.biochem.71.102301.093055. View

Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

Ween M, Armstrong M, Oehler M, Ricciardelli C . The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit Rev Oncol Hematol. 2015; 96(2):220-56. DOI: 10.1016/j.critrevonc.2015.05.012. View

Weidner L, Fung K, Kannan P, Moen J, Kumar J, Mulder J . Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein. Drug Metab Dispos. 2015; 44(2):275-82. PMC: 4746486. DOI: 10.1124/dmd.115.067785. View

10.

Dong X, Zhang M, Ma X, Wang J, Lei Z, Teng Q . Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells. Front Cell Dev Biol. 2020; 8:865. PMC: 7481333. DOI: 10.3389/fcell.2020.00865. View

11.

Cui Q, Wang J, Assaraf Y, Ren L, Gupta P, Wei L . Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat. 2018; 41:1-25. DOI: 10.1016/j.drup.2018.11.001. View

12.

Liao D, Zhang W, Gupta P, Lei Z, Wang J, Cai C . Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression. Molecules. 2019; 24(23). PMC: 6930469. DOI: 10.3390/molecules24234383. View

13.

Friedrich R, Punke C, Reymann A . Expression of multi-drug resistance genes (mdr1, mrp1, bcrp) in primary oral squamous cell carcinoma. In Vivo. 2004; 18(2):133-47. View

14.

Halilovic E, Solit D . Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacol. 2008; 8(4):419-26. DOI: 10.1016/j.coph.2008.06.014. View

15.

Ross D, Karp J, Chen T, Doyle L . Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood. 2000; 96(1):365-8. View

16.

Dean M, Rzhetsky A, Allikmets R . The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001; 11(7):1156-66. DOI: 10.1101/gr.184901. View

17.

Kovalev A, Tsvetaeva D, Grudinskaja T . Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol. 2014; 35(4):287-90. View

18.

Jackson S, Manolaridis I, Kowal J, Zechner M, Taylor N, Bause M . Structural basis of small-molecule inhibition of human multidrug transporter ABCG2. Nat Struct Mol Biol. 2018; 25(4):333-340. DOI: 10.1038/s41594-018-0049-1. View

19.

Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J . Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer. 2003; 108(1):146-51. DOI: 10.1002/ijc.11528. View

20.

Luo X, Teng Q, Dong J, Yang D, Wang M, Dessie W . Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. Front Pharmacol. 2020; 11:1208. PMC: 7438908. DOI: 10.3389/fphar.2020.01208. View